Clinical heterogeneity of Duchenne muscular dystrophy (DMD): Definition of sub-phenotypes and predictive criteria by long-term follow-up

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Desguerre, Isabelle ^a,b   Christov, Christo ^b   Mayer, Michele ^c   Zeller, Reinhard ^d   Becane, Henri Marc ^e   Bastuji Garin, Sylvie ^f   Leturcq, France ^d,e   Chiron, Catherine ^b   Chelly, Jamel ^d,e   Gherardi, Romain K ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Trousseau Hospital ^*  (France)

^e INSTITUT COCHIN   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN;

ADOLESCENT; ADULT; ARTHRODESIS; ARTICLE; CHILD; COGNITION; DIAGNOSTIC ACCURACY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; HEART FAILURE; HEART FUNCTION; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE CONTRACTURE; MUSCLE STRENGTH; ONSET AGE; ORTHOSIS; OUTCOME ASSESSMENT; PHYSIOTHERAPY; RESPIRATORY FUNCTION; TENOTOMY;

EID: 84887212371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004347     Document Type: Article

References (31)

1. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, et al. (1989) Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39: 475-481.
2. Brooke MH, Fenichel GM, Griggs RC, Schumate JB, Pellegrino RJ (1983) Clinical investigation in Duchenne Dystrophy: Determination of the power of therapeutic trials based on natural history. Muscle Nerve 6: 91-103.
3. Mendell JR, Province MA, Griggs RC, Brooke MH, Fenichel GM, et al. (1987) Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls. Arch Neurol 44: 808-811.
4. Sifringer M, Uhlenberg B, Lammel S, Hanke R, Neumann B, et al. (2004) Identification of transcripts from a subtraction library which might be responsible for the mild phenotype in an intrafamilially variable course of Duchenne muscular dystrophy. Hum Genet 114: 149-156.
5. Bushby KM, Apleton R, Anderson LV, Welsch JL, Kelly P, et al. (1995) Deletion status and intellectual impairment in Duchenne muscular dystrophy. Dev Med Child Neurol 37: 260-269.
6. Kapsa R, Kornberg AJ, Byrne E (2003) Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2: 299-310.
7. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, et al. (2005) CINRG randomised controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 58: 151-155.
8. Van Essen AJ, Verheij JBGM, Reefhuis J, Fidler C, Begeer JH, et al. (2004) The natural history of Duchenne muscular dystrophy:analysis of data from a Dutch survey and review of age-related events. Online Leyden Muscular Dystrophy pages. Available: http://www.dmd.nl/. Accessed 11 August 2007.
9. Bushby K (1992) Genetic and clinical correlation of Xp21 muscular dystrophy. J Inher Metab Dis 15: 551-564.
10. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, et al. (1993) Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical and histopathological data. Trends across the clinical groups. J Med Genet 30: 728-736.
11. Allsop KG, Ziter FA (1981) Loss of strength and functional decline in Duchenne's dystrophy. Arch Neurol 38: 406-411.
12. Kilmer DD, Abresch RT, Fowler WM Jr (1993) Serial manual muscle testing in Duchenne muscular dystrophy. Arch Phys Med Rehabil 74: 1168-1171.
13. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, et al. (2006) Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 35: 36-42.
14. Jeppesen J, Green A, Steffensen BF, Rahbek J (2003) The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 13: 804-812.
15. Eagle M, Bourke J, Bullock R Gibson M, Struab V, et al. (2007) Managing Duchenne muscular dystrophy. The additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17: 470-475.
16. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, et al. (2005) Effect of Perindopril on the onset and progression of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy. J Am Coll Cardiol 45: 855-867.
17. Cole TJ, Bellizini MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320: 1240-1243.
18. Wicksell RK, Khilgren M, Melin L, Orvar EO (2004) Specific cognitive deficits are common in children with Duchenne Muscular Dystrophy. Dev Med and Child Neurol 46: 154-156.
19. Deburgrave N, Daoud F, Llense S, Barbot JC, Recan D, et al. (2007) Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 28: 183-195.
20. Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations:one gene, several proteins, multiple phenotypes. Lancet Neurol 2: 731-740.
21. Meulman J, Van der Kooij AJ, Heiser WJ (2004) Principal components analysis with non linear optimal scaling transformations for ordinal and nominal data. In: Kaplan D, ed. Handbook of quantitative methodolgy for the social sciences. Thousand Oaks: Sage Publications, Inc. pp 49-70.
22. Kaminska A, Ickowicz A, Plouin P, Bru MF, Dellatollas G, et al. (1999) Delineation of cryptogenic Lennox Gastaud syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 36: 15-29.
23. Knottnerus JA, van Weel C, Muris JWM (2002) Evidence base of clinical diagnosis: evaluation of diagnostic procedures. BMJ 324: 477-480.
24. Uitenbroek DG (1997) SISA Diagnostic accuracy. Available: http://www.quantitativeskills.com/sisa/statistics/diagnos.htm. Accessed 12 March 2008.
25. Wilcox MA, Wysnzynski DF, Panhuysen CI, Ma Q, Yip A, et al. (2003) Empirically derived phenotypic subgroups - qualitative and quantitative trait analyses. BMC Genetics 4(Suppl 1): S15.
26. Wilcox MA, Wysnzynski DF, Panhuysen CI, Ma Q, Yip A, et al. (2005) Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum 53: 263-271.
27. Chung B, Wong V, Ip P (2004) Spinal muscular amyotrophy: Survival pattern and functional status. Pediatrics 114: 548-553.
28. Bouvier P, Halperin D, Rey H, Jaffe PD, Laederach J, et al. (1999) Typology and correlates of sexual abuse in children and youth: multivariate analyses in a prevalence study in Geneva. Child Abuse Negl 23: 779-790.
29. Prelle A, Medori R, Moggio M, Chan HW, Gallanti A, et al. (1992) Dystrophin deficiency in a case of congenital myopathy. J Neurol 239: 76-78.
30. Mok E, Beghin L, Gauchon P (2006) Estimation body composition in children with Duchenne muscular dystrophy:comparison of bioelectrical impedance analysis and skinfold-thickness measurement. Am J Clin Nutr 83: 63-69.
31. Suthers GK, Davies KE (1992) Phenotypic heterogeneity and the single gene. Am J Hum Genet 50: 887-891.